Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T13:47:12.740Z Has data issue: false hasContentIssue false
  • English
  • Français

Natalizumab Risk Stratification: Role of a Two- Step Anti-JCV Antibody Assay

Published online by Cambridge University Press:  02 December 2014

Paul W. O'Connor
Paul W. O'Connor*
Affiliation:
Department of Neurology, St. Michael's Hospital, Toronto, Ontario, Canada
*
Department of Neurology, St. Michael's Hospital, 30 bond Street, Toronto, Ontario, M5b 1W8, Canada. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 5 , September 2012 , pp. 670 - 675
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Biogen Idec Canada Inc. Tysabri (natalizumab) Product Monograph. November 1, 2010.Google Scholar
2.Polman, CH, O’Connor, PW, Havrdova, E, et al.A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N engl J Med. 2006;354:899–910.Google Scholar
3.Havrdova, E, Galetta, S, Hutchinson, M, et al.Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and efficacy in Relapsing-Remitting Multiple Sclerosis (aFFiRM) study. lancet Neurol. 2009;8:254–60.Google Scholar
4.Balcer, L, Galetta, Sl, Calabresi, PA, et al.Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68:1299–304.CrossRefGoogle ScholarPubMed
5.Rudick, RA, Miller, D, Hass, S, et al; AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62:335–46.CrossRefGoogle ScholarPubMed
6.Agostini, HT, Ryschkewitsch, CF, Singer, EF, Stoner, GL.Coinfection with two JC virus genotypes in brain, cerebrospinal fluid or urinary tract detected by direct cycle sequencing of PCR products. J Neurovirol. 1996;2:259–67.Google Scholar
7.Hellwig, K, Gold, R.Progressive multifocal leukoencephalopathy and natalizumab. J Neurol. 2011;258:1920–8.Google Scholar
8.Sunyaev, SR, Lugovskoy, A, Simon, K, Gorelik, L.adaptive mutation in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PMl). PloS genet. 2009;5:e1000368.Google Scholar
9.Tan, CS, Koralnik, IJ.Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. lancet Neurol. 2010;9:425–37.CrossRefGoogle ScholarPubMed
10.Major, EO.Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. annu Rev Med. 2010;61:35–47.CrossRefGoogle ScholarPubMed
11.Langer-Gould, A, Atlast, SW, Green, AJ, Bollen, AW, Pelletier, D.Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N engl J Med. 2005;353:375–81.CrossRefGoogle Scholar
12.Kleinschmidt-DeMasters, BK, Tyler, KL.Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon-beta-1a for multiple sclerosis. N engl J Med. 2005;353:369–74.CrossRefGoogle ScholarPubMed
13.Van Assche, G, Van Ranst, M, Sciot, R, et al.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N engl J Med. 2005;353:362–8.Google Scholar
14.Biogen, Idec. Data on file as of February 29, 2012.Google Scholar
15.Foley, J, Vermersch, P, Gold, R, et al.Natalizumab-associated progressive multifocal leukoencephalopathy outcomes. int J MS Care. 2011;13(Suppl 3):7.Google Scholar
16.Clifford, DB, De Luca, A, Simpson, DW, Arendt, G, Giovannoni, G, Nath, A.Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons learned from 28 cases. lancet Neurol. 2010;9:438–46.CrossRefGoogle Scholar
17.Khatri, BO, Man, S, Giovannoni, G, et al.effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72:402–9.Google Scholar
18.Vermersch, P, Kappos, L, Gold, R, et al.Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2001;76:1697–704.Google Scholar
19.Gorelik, L, Lerner, M, Bixler, S, et al.Anti-JCV virus antibodies: implications for PMl risk stratification. Ann Neurol. 2010;68:295–303.CrossRefGoogle ScholarPubMed
20.Sørensen, PS, Bbertolotto, A, Edan, G, et al.Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18:143–52.CrossRefGoogle ScholarPubMed
21.Rudick, RA, O’Connor, PW, Polman, CH, et al.Assessment of JC virus DNa in blood and urine from natalizumab-treated patients. Ann Neurol. 2010;68:304–10.CrossRefGoogle ScholarPubMed
22.Bozic, C, Richman, S, Plavina, T, et al.Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742–50.CrossRefGoogle Scholar
23.Moiola, L, Sangalli, F, Martinelli, V, et al.Prevalence of anti-JCV antibodies in a cohort of natalizumab-treated multiople sclerosis patients from italy. Neurology. 2011;76(Suppl 4):S30.007, S31.Google Scholar
24.Bloomgren, G, Richman, S, Hotermans, C, et al.Contribution of natalizumab treatment duration, prior immunosuppressant use, and anti-JCv virus antibody status to the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Mult Scler J. 2011;17(Suppl 10):S451.Google Scholar
25.O’Connor, PW.Use of natalizumab in multiple sclerosis patients. Can J Neurol Sci. 2010;37:98–104.Google Scholar
26.O’Connor, PW, Goodman, A, Kappos, L, et al.Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858–65.CrossRefGoogle ScholarPubMed
27.Kappos, L, Foley, J, Gold, R, et al.Overview of survival outcome and functional status in postmarketing cases of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler J. 2011;17(10 Suppl):S131.Google Scholar
28.Phan-Ba, R, Lommers, E, Tshibanda, L, et al.MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PMl) under natalizumab therapy. J Neurol Neurosurg Psychiatry. 2012;83:224–6.Google Scholar